Stockreport

CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF CRMD's FY25 saw strong profitability: $163.1M net income, $401.3M pro forma revenue, and $77.2M adjusted EBITDA, aided by the Melinta acquisition. CRMD stock trades a [Read more]